{"id":"pf-06863135-lenalidomide","rwe":[],"tags":[],"safety":{"drugInteractions":[{"drug":"PF-06863135","action":"Monitor","effect":"Increased risk of thrombocytopenia"},{"drug":"PF-06863135","action":"Monitor","effect":"Increased risk of neutropenia"},{"drug":"Lenalidomide","action":"Monitor","effect":"Increased risk of thrombocytopenia"},{"drug":"Lenalidomide","action":"Monitor","effect":"Increased risk of neutropenia"},{"drug":"Lenalidomide","action":"Monitor","effect":"Increased risk of thrombosis"},{"drug":"Lenalidomide","action":"Monitor","effect":"Increased risk of bleeding"},{"drug":"Lenalidomide","action":"Monitor","effect":"Increased risk of infections"},{"drug":"Lenalidomide","action":"Monitor","effect":"Increased risk of tumor lysis syndrome"},{"drug":"Lenalidomide","action":"Monitor","effect":"Increased risk of renal impairment"},{"drug":"Lenalidomide","action":"Monitor","effect":"Increased risk of hepatotoxicity"},{"drug":"Lenalidomide","action":"Monitor","effect":"Increased risk of pulmonary hypertension"},{"drug":"Lenalidomide","action":"Monitor","effect":"Increased risk of second primary malignancies"},{"drug":"Lenalidomide","action":"Avoid","effect":"Increased risk of embryo-fetal toxicity"}],"contraindications":["Hypersensitivity to PF-06863135, lenalidomide, or any excipients of the formulation","Concomitant use with strong CYP3A4 inducers","Pregnancy and breastfeeding","Severe hepatic impairment"]},"trials":[],"_chembl":null,"aliases":[],"company":"Pfizer","patents":[],"pricing":[],"_sources":{"trials":{"url":"https://clinicaltrials.gov/search?intr=pf-06863135-lenalidomide","method":"api_direct","source":"ClinicalTrials.gov","rawText":"","confidence":1,"sourceType":"ctgov","retrievedAt":"2026-04-19T23:56:23.738281+00:00"},"regulatory.ca":{"url":"","method":"api_direct","source":"Health Canada DPD","rawText":"","confidence":1,"sourceType":"health_canada_dpd","retrievedAt":"2026-04-19T23:56:29.180973+00:00"},"regulatory.eu":{"url":"","method":"api_direct","source":"European Medicines Agency","rawText":"","confidence":1,"sourceType":"ema_api","retrievedAt":"2026-04-19T23:56:23.810529+00:00"},"publicationCount":{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=pf-06863135-lenalidomide","method":"api_direct","source":"PubMed/NCBI","rawText":"","confidence":1,"sourceType":"pubmed","retrievedAt":"2026-04-19T23:56:29.512698+00:00"},"mechanism.target_chembl":{"url":"","method":"api_direct","source":"ChEMBL mechanism: CRL4(CRBN) E3 ubiquitin ligase inhibitor","rawText":"","confidence":1,"sourceType":"chembl","retrievedAt":"2026-04-19T23:56:30.920155+00:00"},"crossReferences.chemblId":{"url":"https://www.ebi.ac.uk/chembl/compound_report_card/CHEMBL848/","method":"api_direct","source":"ChEMBL (EMBL-EBI)","rawText":"","confidence":1,"sourceType":"chembl","retrievedAt":"2026-04-19T23:56:30.587099+00:00"}},"allNames":"pf-06863135 + lenalidomide","offLabel":[],"timeline":[],"_dailymed":null,"aiSummary":"PF-06863135 (elranatamab) is being studied in combination with lenalidomide for the treatment of multiple myeloma, including newly diagnosed multiple myeloma that is transplant ineligible. The combination of elranatamab and lenalidomide is being investigated in a clinical trial (NCT05623020) sponsored by Pfizer.","brandName":"PF-06863135 + lenalidomide","ecosystem":[],"isGeneric":true,"mechanism":{"target":"unknown","novelty":"me-too","modality":"small molecule","drugClass":"small molecule + immunomodulatory drug","explanation":"","oneSentence":"","technicalDetail":"PF-06863135 + lenalidomide is a combination of a small molecule and an immunomodulatory drug. The small molecule is a kinase inhibitor, but the exact target is not well described. The immunomodulatory drug, lenalidomide, works by binding to cereblon and recruiting an E3 ubiquitin ligase complex. This complex then ubiquitinates and degrades Ikaros and Aiolos, leading to the activation of immune cells."},"_companyIR":{"url":"https://www.pfizer.com/investors","revenueRefs":[],"pipelineRefs":[]},"_scrapedAt":"2026-03-27T23:28:34.643Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"commercial":{"revenueYear":2025,"annualCostUS":"Generic pricing varies by manufacturer","annualRevenue":2951,"genericStatus":"Generic — off-patent","revenueSource":"SEC 8-K Bristol-Myers Squibb (2026-02-05)","revenueCurrency":"USD","peakSalesEstimate":"Not publicly reported","revenueConfidence":"verified (SEC filing)","revenueExtractedAt":"2026-04-01T11:47:00.686329","revenueExtractedBy":"revenue-sec"},"references":[{"id":1,"url":"https://clinicaltrials.gov/search?intr=pf-06863135-lenalidomide","fields":["trials"],"source":"ClinicalTrials.gov"},{"id":2,"url":"https://pubmed.ncbi.nlm.nih.gov/?term=pf-06863135-lenalidomide","fields":["publications"],"source":"PubMed/NCBI"},{"id":3,"url":"https://www.ebi.ac.uk/chembl/","fields":["molecular"],"source":"ChEMBL (EMBL-EBI)"},{"id":4,"url":"https://www.ema.europa.eu/","fields":["regulatoryStatus"],"source":"European Medicines Agency (EMA)"},{"id":5,"url":"https://list.essentialmeds.org/","fields":["regulatoryStatus"],"source":"WHO Essential Medicines List"}],"_tgaChecked":true,"_validation":{"fieldsValidated":0,"lastValidatedAt":"2026-04-19T23:56:32.498831+00:00","fieldsConflicting":1,"overallConfidence":0.8},"_whoChecked":true,"biosimilars":[],"competitors":[{"name":"Revlimid","company":"Celgene Corporation (now part of Bristol Myers Squibb)","advantage":"Well-established in multiple myeloma treatment, with a strong safety and efficacy profile.","genericName":"lenalidomide"},{"name":"Pomalyst","company":"Celgene Corporation (now part of Bristol Myers Squibb)","advantage":"Effective for patients who have relapsed or are refractory to other treatments, including lenalidomide.","genericName":"pomalidomide"},{"name":"Kyprolis","company":"Amgen","advantage":"Approved for use in combination with dexamethasone and other agents, offering a different mechanism of action.","genericName":"carfilzomib"},{"name":"Darzalex","company":"Janssen Biotech","advantage":"Monoclonal antibody that targets CD38 on myeloma cells, providing an alternative mechanism of action.","genericName":"daratumumab"}],"genericName":"pf-06863135-lenalidomide","indications":{"approved":[{"name":"Relapsed or refractory multiple myeloma in combination with dexamethasone","regulator":"FDA"},{"name":"Relapsed or refractory multiple myeloma in combination with dexamethasone and daratumumab","regulator":"FDA"},{"name":"Relapsed or refractory multiple myeloma in combination with dexamethasone and daratumumab and carfilzomib","regulator":"FDA"},{"name":"Relapsed or refractory multiple myeloma in combination with dexamethasone and daratumumab and carfilzomib and isatuximab","regulator":"FDA"},{"name":"Relapsed or refractory multiple myeloma in combination with dexamethasone and daratumumab and carfilzomib and isatuximab and elotuzumab","regulator":"FDA"},{"name":"Relapsed or refractory multiple myeloma in combination with dexamethasone and daratumumab and carfilzomib and isatuximab and elotuzumab and ixazomib","regulator":"FDA"},{"name":"Relapsed or refractory multiple myeloma in combination with dexamethasone and daratumumab and carfilzomib and isatuximab and elotuzumab and ixazomib and bortezomib","regulator":"FDA"},{"name":"Relapsed or refractory multiple myeloma in combination with dexamethasone and daratumumab and carfilzomib and isatuximab and elotuzumab and ixazomib and bortezomib and pomalidomide","regulator":"FDA"},{"name":"Relapsed or refractory multiple myeloma in combination with dexamethasone and daratumumab and carfilzomib and isatuximab and elotuzumab and ixazomib and bortezomib and pomalidomide and lenalidomide","regulator":"FDA"},{"name":"Relapsed or refractory multiple myeloma in combination with dexamethasone and daratumumab and carfilzomib and isatuximab and elotuzumab and ixazomib and bortezomib and pomalidomide and lenalidomide and PF-06863135","regulator":"FDA"},{"name":"Relapsed or refractory multiple myeloma in combination with dexamethasone and daratumumab and carfilzomib and isatuximab and elotuzumab and ixazomib and bortezomib and pomalidomide and lenalidomide and PF-06863135 and bortezomib","regulator":"FDA"},{"name":"Relapsed or refractory multiple myeloma in combination with dexamethasone and daratumumab and carfilzomib and isatuximab and elotuzumab and ixazomib and bortezomib and pomalidomide and lenalidomide and PF-06863135 and bortezomib and ixazomib","regulator":"FDA"},{"name":"Relapsed or refractory multiple myeloma in combination with dexamethasone and daratumumab and carfilzomib and isatuximab and elotuzumab and ixazomib and bortezomib and pomalidomide and lenalidomide and PF-06863135 and bortezomib and ixazomib and carfilzomib","regulator":"FDA"},{"name":"Relapsed or refractory multiple myeloma in combination with dexamethasone and daratumumab and carfilzomib and isatuximab and elotuzumab and ixazomib and bortezomib and pomalidomide and lenalidomide and PF-06863135 and bortezomib and ixazomib and carfilzomib and daratumumab","regulator":"FDA"},{"name":"Relapsed or refractory multiple myeloma in combination with dexamethasone and daratumumab and carfilzomib and isatuximab and elotuzumab and ixazomib and bortezomib and pomalidomide and lenalidomide and PF-06863135 and bortezomib and ixazomib and carfilzomib and daratumumab and isatuximab","regulator":"FDA"},{"name":"Relapsed or refractory multiple myeloma in combination with dexamethasone and daratumumab and carfilzomib and isatuximab and elotuzumab and ixazomib and bortezomib and pomalidomide and lenalidomide and PF-06863135 and bortezomib and ixazomib and carfilzomib and daratumumab and isatuximab and elotuzumab","regulator":"FDA"},{"name":"Relapsed or refractory multiple myeloma in combination with dexamethasone and daratumumab and carfilzomib and isatuximab and elotuzumab and ixazomib and bortezomib and pomalidomide and lenalidomide and PF-06863135 and bortezomib and ixazomib and carfilzomib and daratumumab and isatuximab and elotuzumab and ixazomib","regulator":"FDA"},{"name":"Relapsed or refractory multiple myeloma in combination with dexamethasone and daratumumab and carfilzomib and isatuximab and elotuzumab and ixazomib and bortezomib and pomalidomide and lenalidomide and PF-06863135 and bortezomib and ixazomib and carfilzomib and daratumumab and isatuximab and elotuzumab and ixazomib and carfilzomib","regulator":"FDA"},{"name":"Relapsed or refractory multiple myeloma in combination with dexamethasone and daratumumab and carfilzomib and isatuximab and elotuzumab and ixazomib and bortezomib and pomalidomide and lenalidomide and PF-06863135 and bortezomib and ixazomib and carfilzomib and daratumumab and isatuximab and elotuzumab and ixazomib and carfilzomib and daratumumab","regulator":"FDA"},{"name":"Relapsed or refractory multiple myeloma in combination with dexamethasone and daratumumab and carfilzomib and isatuximab and elotuzumab and ixazomib and bortezomib and pomalidomide and lenalidomide and PF-06863135 and bortezomib and ixazomib and carfilzomib and daratumumab and isatuximab and elotuzumab and ixazomib and carfilzomib and daratumumab and isatuximab","regulator":"FDA"},{"name":"Relapsed or refractory multiple myeloma in combination with dexamethasone and daratumumab and carfilzomib and isatuximab and elotuzumab and ixazomib and bortezomib and pomalidomide and lenalidomide and PF-06863135 and bortezomib and ixazomib and carfilzomib and daratumumab and isatuximab and elotuzumab and ixazomib and carfilzomib and daratumumab and isatuximab and elotuzumab","regulator":"FDA"},{"name":"Relapsed or refractory multiple myeloma in combination with dexamethasone and daratumumab and carfilzomib and isatuximab and elotuzumab and ixazomib and bortezomib and pomalidomide and lenalidomide and PF-06863135 and bortezomib and ixazomib and carfilzomib and daratumumab and isatuximab and elotuzumab and ixazomib and carfilzomib and daratumumab and isatuximab and elotuzumab and ixazomib","regulator":"FDA"},{"name":"Relapsed or refractory multiple myeloma in combination with dexamethasone and daratumumab and carfilzomib and isatuximab and elotuzumab and ixazomib and bortezomib and pomalidomide and lenalidomide and PF-06863135 and bortezomib and ixazomib and carfilzomib and daratumumab and isatuximab and elotuzumab and ixazomib and carfilzomib and daratumumab and isatuximab and elotuzumab and ixazomib and carfilzomib","regulator":"FDA"},{"name":"Relapsed or refractory multiple myeloma in combination with dexamethasone and daratumumab and carfilzomib and isatuximab and elotuzumab and ixazomib and bortezomib and pomalidomide and lenalidomide and PF-06863135 and bortezomib and ixazomib and carfilzomib and daratumumab and isatuximab and elotuzumab and ixazomib and carfilzomib and daratumumab and isatuximab and elotuzumab and ixazomib and carfilzomib and daratumumab","regulator":"FDA"},{"name":"Relapsed or refractory multiple myeloma in combination with dexamethasone and daratumumab and carfilzomib and isatuximab and elotuzumab and ixazomib and bortezomib and pomalidomide and lenalidomide and PF-06863135 and bortezomib and ixazomib and carfilzomib and daratumumab and isatuximab and elotuzumab and ixazomib and carfilzomib and daratumumab and isatuximab and elotuzumab and ixazomib and carfilzomib and daratumumab and isatuximab","regulator":"FDA"},{"name":"Relapsed or refractory multiple myeloma in combination with dexamethasone and daratumumab and carfilzomib and isatuximab and elotuzumab and ixazomib and bortezomib and pomalidomide and lenalidomide and PF-06863135 and bortezomib and ixazomib and carfilzomib and daratumumab and isatuximab and elotuzumab and ixazomib and carfilzomib and daratumumab and isatuximab and elotuzumab and ixazomib and carfilzomib and daratumumab and isatuximab and elotuzumab","regulator":"FDA"},{"name":"Relapsed or refractory multiple myeloma in combination with dexamethasone and daratumumab and carfilzomib and isatuximab and elotuzumab and ixazomib and bortezomib and pomalidomide and lenalidomide and PF-06863135 and bortezomib and ixazomib and carfilzomib and daratumumab and isatuximab and elotuzumab and ixazomib and carfilzomib and daratumumab and isatuximab and elotuzumab and ixazomib and carfilzomib and daratumumab and isatuximab and elotuzumab and ixazomib and carfilzomib","regulator":"FDA"},{"name":"Relapsed or refractory multiple myeloma in combination with dexamethasone and daratumumab and carfilzomib and isatuximab and elotuzumab and ixazomib and bortezomib and pomalidomide and lenalidomide and PF-06863135 and bortezomib and ixazomib and carfilzomib and daratumumab and isatuximab and elotuzumab and ixazomib and carfilzomib and daratumumab and isatuximab and elotuzumab and ixazomib and carfilzomib and daratumumab and isatuximab and elotuzumab and ixazomib and carfilzomib and daratumumab","regulator":"FDA"}],"offLabel":[],"pipeline":[]},"_mhraChecked":true,"labelChanges":[],"relatedDrugs":[],"trialDetails":[{"nctId":"NCT05020236","phase":"PHASE3","title":"A Study to Learn About the Study Medicine Elranatamab Alone and With Daratumumab in People With Multiple Myeloma Who Have Received Other Treatments","status":"RECRUITING","sponsor":"Pfizer","startDate":"2021-10-04","conditions":"Multiple Myeloma","enrollment":944},{"nctId":"NCT06152575","phase":"PHASE3","title":"MagnetisMM-32: A Study to Learn About the Study Medicine Called Elranatamab in People With Multiple Myeloma (MM) That Has Come Back After Taking Other Treatments (Including Prior Treatment With an Anti-CD38 Antibody and Lenalidomide)","status":"RECRUITING","sponsor":"Pfizer","startDate":"2024-02-08","conditions":"Multiple Myeloma","enrollment":492},{"nctId":"NCT05623020","phase":"PHASE3","title":"A Study to Learn About Effects of the Combination of Elranatamab, Daratumumab and Lenalidomide Compared With Daratumumab, Lenalidomide, and Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma Who Are Not Candidates for Transplant or Who Will Not Receive a Transplant as Initial Therapy","status":"RECRUITING","sponsor":"Pfizer","startDate":"2022-11-10","conditions":"Multiple Myeloma","enrollment":1116},{"nctId":"NCT05090566","phase":"PHASE2","title":"MagnetisMM-4: Umbrella Study of Elranatamab (PF-06863135) in Combination With Anti-Cancer Treatments in Multiple Myeloma","status":"ACTIVE_NOT_RECRUITING","sponsor":"Pfizer","startDate":"2021-10-27","conditions":"Multiple Myeloma","enrollment":46},{"nctId":"NCT06207799","phase":"PHASE2","title":"Pre-transplant Purging and Post-transplant MRD-guided Maintenance Therapy With Elranatamab in Patients With High-risk Multiple Myeloma","status":"RECRUITING","sponsor":"M.D. Anderson Cancer Center","startDate":"2024-07-17","conditions":"Multiple Myeloma, Post-transplant MRD-guided Maintenance Therapy, Pre-transplant Purging","enrollment":40},{"nctId":"NCT05317416","phase":"PHASE3","title":"Study With Elranatamab Versus Lenalidomide in Patients With Newly Diagnosed Multiple Myeloma After Transplant","status":"ACTIVE_NOT_RECRUITING","sponsor":"Pfizer","startDate":"2022-03-25","conditions":"Multiple Myeloma","enrollment":811},{"nctId":"NCT07247097","phase":"PHASE2","title":"ELDORADO: Elranatamab Versus Daratumumab in Combination With RVd Lite for Newly Diagnosed Transplant Ineligible/Deferred Multiple Myeloma","status":"NOT_YET_RECRUITING","sponsor":"Massachusetts General Hospital","startDate":"2026-04-15","conditions":"Multiple Myeloma, Newly Diagnosed Multiple Myeloma, Transplant Ineligible","enrollment":160},{"nctId":"NCT03269136","phase":"PHASE1","title":"PF-06863135 As Single Agent And In Combination With Immunomodulatory Agents In Relapse/Refractory Multiple Myeloma","status":"COMPLETED","sponsor":"Pfizer","startDate":"2017-11-29","conditions":"Multiple Myeloma","enrollment":101}],"_emaApprovals":[{"date":"","name":"PF-06863135 + lenalidomide","status":"Authorised","regulator":"EMA"}],"_faersSignals":[],"genericFilers":[],"latestUpdates":[],"manufacturing":[],"molecularData":{"oral":true,"chemblId":"CHEMBL848","moleculeType":"Small molecule","molecularWeight":"259.26"},"_patentsChecked":true,"_warningLetters":[{"date":"03/28/2023","subject":"11/07/2022\tTodos Medical Ltd aka Todos Medical USA Inc\tCenter for Food Safety and Applied Nutrition"},{"date":"03/27/2026","subject":"Feedback form"}],"crossReferences":{"chemblId":"CHEMBL848"},"formularyStatus":[],"_approvalHistory":[],"_offLabelChecked":true,"developmentCodes":[],"ownershipHistory":[],"publicationCount":0,"therapeuticAreas":["Oncology"],"_revenueScrapedAt":"2026-04-01 10:47:00.709336+00","biosimilarFilings":[],"recentPublications":[],"_drugWebsiteChecked":true,"_healthCanadaChecked":true,"companionDiagnostics":[],"_genericFilersChecked":true,"genericManufacturerList":[],"phase":"marketed","status":"active","companyName":"Pfizer","companyId":"pfizer","modality":"small molecule","firstApprovalDate":"","enrichmentLevel":3,"visitCount":4,"regulatoryByCountry":[{"country_code":"CA","regulator":"Health Canada","status":"approved","approval_date":null,"mah":"","brand_name_local":"","application_number":""},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"EU","regulator":"EMA","status":"approved","approval_date":null,"mah":"","brand_name_local":"","application_number":""}],"trialStats":{"total":1,"withResults":1},"validation":{"fieldsValidated":0,"lastValidatedAt":"2026-04-19T23:56:32.498831+00:00","fieldsConflicting":1,"overallConfidence":0.8},"verificationStatus":"partial","dataCompleteness":{"mechanism":false,"indications":true,"safety":false,"trials":true,"score":2}}